FLT3 and acute myeloid leukemia: Quizartinib (AC220, Daiichi Sankyo) and gilteritinib (ASP2215, Astellas) are FLT3-specific inhibitors classified as potent second-generation drugs [6, 11–13] and currently under clinical consideration for use in FLT3-ITD-positive AML patients.